# EDGAR Filing Document

**Accession Number:** 0000921114
**File Stem:** 0001104659-25-080910
**Filing Date:** 2025-8
**Character Count:** 2647
**Document Hash:** 223b4b9ea22b286dbf550f93817757ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-080910.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0001104659-25-080910

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250820

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Armata Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0000921114
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911549568
- **STATE OF INCORPORATION:** WA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066
- **BUSINESS PHONE:** 310-665-2928

**MAIL ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AmpliPhi Biosciences Corp
- **DATE OF NAME CHANGE:** 20130222

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TARGETED GENETICS CORP /WA/
- **DATE OF NAME CHANGE:** 19940331

![](tm2523066d2_correspimg001.jpg)

August 20, 2025

**<u>VIA EDGAR SUBMISSION</u>**

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

---

| | |
|:---|:---|
| **Re:** | **Armata Pharmaceuticals, Inc. (the "Company")**<br> **Registration Statement on Form S-3 (File No. 333-289585) (the "Registration Statement")** |

---

Dear Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended (the "Securities Act"), the Company hereby requests that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Friday, August 22, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

If you have any questions regarding this request, please contact our outside counsel, Andrew C. Marmer of Willkie Farr & Gallagher LLP, at (212)-728-8847 or the undersigned at (310)-626-0538. Please also call Andrew C. Marmer as soon as the Company's Registration Statement on Form S-3 has been declared effective. Thank you for your attention to this matter.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| **ARMATA PHARMACEUTICALS, INC.** | **ARMATA PHARMACEUTICALS, INC.** |
| By: | /s/ David House |
| Name: David House | Name: David House |
| Title: Senior Vice President, Finance and Principal Financial Officer | Title: Senior Vice President, Finance and Principal Financial Officer |

---

cc: Andrew C. Marmer, Willkie Farr & Gallagher LLP